159 related articles for article (PubMed ID: 30854978)
1. Optimization of Microemulgel for Tizanidine Hydrochloride.
Jagdale S; Brahmane S; Chabukswar A
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):158-179. PubMed ID: 30854978
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Microemulsion Based Transdermal Gel of Triamcinolone.
Jagdale S; Chaudhari B
Recent Pat Antiinfect Drug Discov; 2017; 12(1):61-78. PubMed ID: 28506203
[TBL] [Abstract][Full Text] [Related]
3. Development of Microemulsion Based Nabumetone Transdermal Delivery for Treatment of Arthritis.
Jagdale SC; Deore GK; Chabukswar AR
Recent Pat Drug Deliv Formul; 2018; 12(2):130-149. PubMed ID: 29485013
[TBL] [Abstract][Full Text] [Related]
4. An approach to switching patients from baclofen to tizanidine.
Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
[TBL] [Abstract][Full Text] [Related]
5. Formulation development, in vitro and in vivo evaluation of microemulsion-based gel loaded with ketoprofen.
Nikumbh KV; Sevankar SG; Patil MP
Drug Deliv; 2015; 22(4):509-15. PubMed ID: 24266589
[TBL] [Abstract][Full Text] [Related]
6. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
Shah N; Seth A; Balaraman R; Sailor G; Javia A; Gohil D
Drug Dev Ind Pharm; 2018 Apr; 44(4):687-696. PubMed ID: 29168671
[TBL] [Abstract][Full Text] [Related]
7. Formulation Optimization and Ex Vivo and In Vivo Evaluation of Celecoxib Microemulsion-Based Gel for Transdermal Delivery.
Cao M; Ren L; Chen G
AAPS PharmSciTech; 2017 Aug; 18(6):1960-1971. PubMed ID: 27914040
[TBL] [Abstract][Full Text] [Related]
8. Update on tizanidine for muscle spasticity and emerging indications.
Malanga G; Reiter RD; Garay E
Expert Opin Pharmacother; 2008 Aug; 9(12):2209-15. PubMed ID: 18671474
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
10. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
12. Application of D-Optimal Mixture Design in the Development of Nanocarrier-Based Darifenacin Hydrobromide Gel.
Patel D; Menon M; Shah P; Patel M; Lalan M
Recent Adv Drug Deliv Formul; 2023; 17(1):47-60. PubMed ID: 36809940
[TBL] [Abstract][Full Text] [Related]
13. Development of Solid Self-Microemulsifying System of Tizanidine Hydrochloride for Oral Bioavailability Enhancement: In Vitro and In Vivo Evaluation.
Pramanik S; Thakkar H
AAPS PharmSciTech; 2020 Jul; 21(5):182. PubMed ID: 32613377
[TBL] [Abstract][Full Text] [Related]
14. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
15. Microemulgel of Voriconazole: an Unfathomable Protection to Counter Fungal Contagiousness.
Ashara KC; Paun JS; Soniwala MM; Chavda JR
Folia Med (Plovdiv); 2017 Dec; 59(4):461-471. PubMed ID: 29341946
[TBL] [Abstract][Full Text] [Related]
16. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Kamen L; Henney HR; Runyan JD
Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
[TBL] [Abstract][Full Text] [Related]
17. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
18. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
19. Development, characterization and evaluation of ginger extract loaded microemulsion: In vitro and Ex vivo release studies.
Akram A; Akhtar N; Waqas MK; Rasul A; Rehman KU; Khan J; Iqbal M; Khan BA
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1873-1877. PubMed ID: 31680086
[TBL] [Abstract][Full Text] [Related]
20. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
